Cernostics Announces Groundbreaking Data Demonstrating TissueCypher® Performance for Predicting Risk of Progression to EAC in Patients with Non-Dysplastic BE

  First-of-its-kind precision medicine test for esophageal pinch biopsies identifies high risk non-dysplastic BE patients that progress to EAC at rates higher than expert-confirmed LGD   Pittsburgh, Penn., March 3, 2020 ̵ Cernostics, a lea... Read more
Customer Service

Mon-Fri 9am-5pm (EST)